Literature DB >> 16047191

Distribution of gadomelitol in a human breast tumor model in mice.

C Corot1, P Robert, E Lancelot, A Martinell, R Santus.   

Abstract

The study evaluates the tumor distribution of the rapid clearance blood pool agent (RCBPA) gadomelitol, in a breast tumor model. Different techniques were used : (1) tissue gadolinium concentrations measured by inductively coupled plasma atomic emission spectroscopy (ICP-AES), (2) whole body quantitative autoradiography using radiolabeled [153Gd] gadomelitol and (3) dynamic contrast-enhanced MRI with compartmental analysis. An accumulation of gadomelitol in tumors compared to muscle was observed 30 min and 3 h post injection (p.i.). Thirty minutes p.i., the gadomelitol tumor distribution evaluated by autoradiography showed a marked difference between the rim and the center, whereas both areas showed comparable concentrations after 3 h. Using dynamic contrast-enhanced MRI, three phases could be observed during the 1 hour observation period: (1) rapid tumor uptake within the first few minutes post-injection (2) a progressive increase in tumor signal enhancement over 10 min and (3) a steady-state phase. Average +/- SD (n=5) transendothelial permeability K(PS) and the fractional blood volume fBV were 12.2+/-1.6 microl/min(-1)/g and 5.4+/-0.2% respectively. Due to its slow extravasation and high tumor residence time, gadomelitol may potentially be useful to improve characterization between benign versus malignant tumors using dynamic MRI.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16047191     DOI: 10.1007/s10334-005-0105-9

Source DB:  PubMed          Journal:  MAGMA        ISSN: 0968-5243            Impact factor:   2.310


  15 in total

1.  Safety and pharmacokinetics of p792, a new blood-pool agent: results of clinical testing in nonpatient volunteers.

Authors:  S Gaillard; C Kubiak; C Stolz; B Bonnemain; D Chassard
Journal:  Invest Radiol       Date:  2002-04       Impact factor: 6.016

2.  Comparison of the tumoral biodistribution of P792, a rapid clearance blood pool agent and Gd-DOTA in a C6 glioma cerebral tumor model in rats.

Authors:  P Robert; R Santus; X Violas; C Rémy; C Corot
Journal:  Acad Radiol       Date:  2002-08       Impact factor: 3.173

3.  Modulation of the pharmacokinetics of macromolecular contrast material by avidin chase: MRI, optical, and inductively coupled plasma mass spectrometry tracking of triply labeled albumin.

Authors:  Hagit Dafni; Assaf Gilead; Nava Nevo; Raya Eilam; Alon Harmelin; Michal Neeman
Journal:  Magn Reson Med       Date:  2003-11       Impact factor: 4.668

4.  Assessment of a rapid clearance blood pool MR contrast medium (P792) for assays of microvascular characteristics in experimental breast tumors with correlations to histopathology.

Authors:  K Turetschek; E Floyd; D M Shames; T P Roberts; A Preda; V Novikov; C Corot; W O Carter; R C Brasch
Journal:  Magn Reson Med       Date:  2001-05       Impact factor: 4.668

5.  Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts.

Authors:  Z M Bhujwalla; D Artemov; K Natarajan; E Ackerstaff; M Solaiyappan
Journal:  Neoplasia       Date:  2001 Mar-Apr       Impact factor: 5.715

Review 6.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review.

Authors:  H Maeda; J Wu; T Sawa; Y Matsumura; K Hori
Journal:  J Control Release       Date:  2000-03-01       Impact factor: 9.776

Review 7.  Macromolecular contrast agents for MR mammography: current status.

Authors:  Heike E Daldrup-Link; Robert C Brasch
Journal:  Eur Radiol       Date:  2002-10-31       Impact factor: 5.315

8.  Reduced capillary perfusion and permeability in human tumour xenografts treated with the VEGF signalling inhibitor ZD4190: an in vivo assessment using dynamic MR imaging and macromolecular contrast media.

Authors:  C Pradel; N Siauve; G Bruneteau; O Clement; C de Bazelaire; F Frouin; S R Wedge; J L Tessier; P H Robert; G Frija; C A Cuenod
Journal:  Magn Reson Imaging       Date:  2003-10       Impact factor: 2.546

9.  New model for analysis of dynamic contrast-enhanced MRI data distinguishes metastatic from nonmetastatic transplanted rodent prostate tumors.

Authors:  Xiaobing Fan; Milica Medved; Jonathan N River; Marta Zamora; Claire Corot; Philippe Robert; Philippe Bourrinet; Martin Lipton; Rita M Culp; Gregory S Karczmar
Journal:  Magn Reson Med       Date:  2004-03       Impact factor: 4.668

10.  Comparison of plasma and peritoneal concentrations of various categories of MRI blood pool agents in a murine experimental pharmacokinetic model.

Authors:  F Bourasset; A Dencausse; P Bourrinet; M Ducret; C Corot
Journal:  MAGMA       Date:  2001-05       Impact factor: 2.533

View more
  1 in total

1.  An iron-based T1 contrast agent made of iron-phosphate complexes: in vitro and in vivo studies.

Authors:  Elisenda Rodríguez; Rui V Simoes; Anna Roig; Elies Molins; Nataliya Nedelko; Anna Slawska-Waniewska; Silvio Aime; Carles Arús; Miquel E Cabañas; Coral Sanfeliu; Sebastián Cerdán; Maria Luisa García-Martín
Journal:  MAGMA       Date:  2007-02-01       Impact factor: 2.310

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.